Nobel Prize For Ron

Discussion in 'Acorda Therapeutics' started by anonymous, Jan 22, 2019 at 4:52 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Very funny ! But the inhaled meds is a game changer that no one else in the world of pharma had conceived.
     

  2. anonymous

    anonymous Guest

    Ever heard of a BONG?
    Is this nifty device used to inhale marijuana smoke filtered thru water.

    I was a fan of it in my 90s during college for medicinal use of cannabinoid products to improve my attention and performance.

    Inhaled pharmaceuticals have been around for awhile. That's my point.

    Let's hope Acorda can market ethically plenty of Inbrija. Investors demand no less.
     
  3. anonymous

    anonymous Guest

    Habib, we have been through this. Remember Exubera and Affreza? Both colossal failures in a bigger market with a higher unmet need.

    You might want to focus on success in the US (where you are approved and where your price point will only require a PA or LMN) before you count on countries where you aren’t approved and won’t pay for an alternate delivery of a generic.

    Don’t count your goats before they are born my little propagandist.
     
  4. anonymous

    anonymous Guest

    Omg his ego would know no bounds. It would have its own zip code.
     
  5. anonymous

    anonymous Guest

    2021 Nobel Prize for Medicine to be awarded to Doctor Ronald Cohen
     
  6. anonymous

    anonymous Guest

    Nobel committee says “who”?
     
  7. anonymous

    anonymous Guest

    Attention All Acordians: It's that time of the year to submit names for Nobel nomination. However Dr Cohen would have a difficult climb this year with the Covid vacinnation doctors and scientists likely and justifiably taking top honors. So it would make more sense to hold off until 2022 when Inbrija has become ubiquitous worldwide and PD has been conquered ! Only a suggestion as we know the love of Dr Cohen is indeed great.
     
  8. anonymous

    anonymous Guest

    BREAKING NEWS: PR Newswire 12-26-2020

    Nobel Committee announces sweeping changes to the criteria for the Nobel prize in Medicine.

    Extra points will be awarded to those who have maintained a compensation of 30% above their peer group while eroding value by 98% and increasing debt.

    Further points will be awarded for having a specialty priced generic that has had more product returned for dating than has been given to patients.

    Having reviewed all possible candidates, it has been determined that only Dr. Cohen fits the criteria for this years Nobel Prize in Medicine.

    To further ensure his well deserved prize, all votes will be tabulated by Dominion machines to ensure any votes erroneously cast for a less deserving candidate are properly switched.

    Congrats Dr. Cohen!
     
  9. anonymous

    anonymous Guest

    This would be a dream come true !!!!!!!!! We all love our Dr. Cohn !!!!! Please keep the faith and be ready to support a nomination, whenever it comes. As previous suggest the Covid stars are the big odds on favorite this coming year. Maybe a miracle happen and our candidate will get it ! After all conquering PD is a big deal also.
     
  10. anonymous

    anonymous Guest

    Cannot say Inbrija totally conquered PD but sure put a big dent in it. Whether or not that is enough to win a Nobel is debatable as we see by the huge interest and number of posts. Let s have a serious dialog on this!
     
  11. anonymous

    anonymous Guest

    Your recent quarter implies <1,000 prescriptions a month, hardly a big dent for US, much less the world. Stop with the ridiculous diversions of NOBEL, and redirect those efforts to sales and performance. Habib holes efforts on here are useless, a poor spend. Word your efforts internally to rally employees, not on an anatomy’s board like a 12 year old on tick tock.
     
  12. anonymous

    anonymous Guest

    Time to push forward on this. Feb 1st is the time to start submissions ! Treating PD is a worthy criterion and we have a chance to raise Acorda to worldwide prominence .